{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:46:36Z","timestamp":1791891996561,"version":"4.3.4"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"S5","license":[{"start":{"date-parts":[[2001,10,1]],"date-time":"2001-10-01T00:00:00Z","timestamp":1001894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Recent research has focused on the role of angiogenic growth factors and their ability to mediate tumor growth and metastases, both in solid tumors and in hematologic malignancies. The bone marrow microenvironment is the setting for a wealth of complex interactions that include cell-to-cell contacts as well as secretion of and response to soluble factors. Abundant evidence supports the role of basic fibroblast growth factor (bFGF) in contributing to the dysregulation of apoptosis that is the hallmark of chronic lymphocytic leukemia (CLL). In fact, CLL cells themselves express bFGF; intracellular levels of this cytokine correlate with clinical CLL stage. Other stromal factors mediate the inhibition of apoptosis in CLL as well, suggesting that strategies to block the responses of CLL cells to these factors may represent effective therapies. More broadly, the class of agents known as angiogenesis inhibitors may offer important advantages with respect to the treatment of numerous types of malignancies. Currently, a number of clinical trials are under way to evaluate the clinical potential of several different angiogenesis inhibitors in several hematologic neoplasms.<\/jats:p>","DOI":"10.1634\/theoncologist.6-suppl_5-4","type":"journal-article","created":{"date-parts":[[2004,8,25]],"date-time":"2004-08-25T16:23:52Z","timestamp":1093451032000},"page":"4-7","source":"Crossref","is-referenced-by-count":30,"title":["Angiogenic Growth Factors: Autocrine and Paracrine Regulation of Survival in Hematologic Malignancies"],"prefix":"10.1093","volume":"6","author":[{"given":"Janice L.","family":"Gabrilove","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, The Derald H. Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2001,10,1]]},"reference":[{"key":"2021122211353874900_R1","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1182\/blood.V83.8.2023.2023","article-title":"Interleukin 11: a multifunctional growth factor derived from the hematopoietic microenvironment","volume":"83","author":"Du","year":"1994","journal-title":"Blood"},{"key":"2021122211353874900_R2","doi-asserted-by":"crossref","first-page":"R217","DOI":"10.1016\/S1074-5521(99)80081-7","article-title":"Molecular angiogenesis","volume":"6","author":"Klagsbrun","year":"1999","journal-title":"Chem Biol"},{"key":"2021122211353874900_R3","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1161\/01.CIR.90.2.649","article-title":"Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only","volume":"90","author":"Brogi","year":"1994","journal-title":"Circulation"},{"key":"2021122211353874900_R4","first-page":"728","article-title":"Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies","volume":"59","author":"Bellamy","year":"1999","journal-title":"Cancer Res"},{"key":"2021122211353874900_R5","first-page":"815","article-title":"Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia","volume":"150","author":"Perez-Atayde","year":"1997","journal-title":"Am J Pathol"},{"key":"2021122211353874900_R6","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2141.1994.tb08304.x","article-title":"Bone marrow angiogenesis and progression in multiple myeloma","volume":"87","author":"Vacca","year":"1994","journal-title":"Br J Haematol"},{"key":"2021122211353874900_R7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0065-230X(00)79005-1","article-title":"The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms","volume":"79","author":"Ghia","year":"2000","journal-title":"Adv Cancer Res"},{"key":"2021122211353874900_R8","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/stem.170306","article-title":"Apoptosis","volume":"17","author":"Israels","year":"1999","journal-title":"Stem Cells"},{"key":"2021122211353874900_R9","first-page":"107","article-title":"Chronic lymphocytic leukemia","volume":"26","author":"Keating","year":"1999","journal-title":"Semin Oncol"},{"issue":"suppl 7","key":"2021122211353874900_R10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0037-1963(00)90055-6","article-title":"Apoptosis and cancer: strategies for integrating programmed cell death","volume":"37","author":"Reed","year":"2000","journal-title":"Semin Hematol"},{"key":"2021122211353874900_R11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00001622-200001000-00004","article-title":"Update on the biology of chronic lymphocytic leukemia","volume":"12","author":"Bannerji","year":"2000","journal-title":"Curr Opin Oncol"},{"key":"2021122211353874900_R12","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood.V87.3.1056.bloodjournal8731056","article-title":"Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine","volume":"87","author":"Menzel","year":"1996","journal-title":"Blood"},{"key":"2021122211353874900_R13","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.leu.2400556","article-title":"Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis","volume":"11","author":"Konig","year":"1997","journal-title":"Leukemia"},{"key":"2021122211353874900_R14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3109\/08977199709002111","article-title":"Low level expression of basic FGF upregulates Bcl-2 and delays apoptosis, but high intracellular levels are required to induce transformation in NIH 3T3 cells","volume":"15","author":"Wieder","year":"1997","journal-title":"Growth Factors"},{"key":"2021122211353874900_R15","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood.V96.8.2655","article-title":"Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1","volume":"96","author":"Burger","year":"2000","journal-title":"Blood"},{"key":"2021122211353874900_R16","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.leu.2401275","article-title":"Fibronectin interaction with \u03b14\u03b21 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax","volume":"13","author":"Fuente","year":"1999","journal-title":"Leukemia"},{"key":"2021122211353874900_R17","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","article-title":"Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor","volume":"96","author":"Heinrich","year":"2000","journal-title":"Blood"},{"key":"2021122211353874900_R18","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood.V91.4.1206","article-title":"Thrombopoietin, kit ligand, and flk2\/flt3 ligand together induce increased numbers of primitive hematopoietic progenitors from human CD34+Thy-1+Lin\u2013 cells with preserved ability to engraft SCID-hu bone","volume":"91","author":"Luens","year":"1998","journal-title":"Blood"},{"issue":"suppl 5","key":"2021122211353874900_R19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1634\/theoncologist.6-suppl_5-24","article-title":"Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies","volume":"6","author":"List","year":"2001","journal-title":"The Oncologist"},{"issue":"suppl 5","key":"2021122211353874900_R20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1634\/theoncologist.6-suppl_5-32","article-title":"The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies","volume":"6","author":"Giles","year":"2001","journal-title":"The Oncologist"},{"key":"2021122211353874900_R21","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1146\/annurev.med.49.1.407","article-title":"Angiogenesis and tumor metastasis","volume":"49","author":"Zetter","year":"1998","journal-title":"Annu Rev Med"},{"key":"2021122211353874900_R22","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1517\/13543784.7.10.1629","article-title":"Anti-angiogenic therapies in cancer clinical trials","volume":"7","author":"Zhang","year":"1998","journal-title":"Expert Opin Investig Drugs"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.6-suppl_5-4","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.6-suppl_5-4","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/6\/S5\/4\/41838168\/oncolo_6_s5_4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/6\/S5\/4\/41838168\/oncolo_6_s5_4.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T18:37:25Z","timestamp":1640198245000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/6\/S5\/4\/6386983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10,1]]},"references-count":22,"aliases":["10.1634\/theoncologist.6-2004-4"],"journal-issue":{"issue":"S5","published-online":{"date-parts":[[2001,10,1]]},"published-print":{"date-parts":[[2001,10,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.6-suppl_5-4","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2001,10,1]]},"published":{"date-parts":[[2001,10,1]]}}}